Tags

Type your tag names separated by a space and hit enter

Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
Lancet. 1979 Apr 14; 1(8120):803-5.Lct

Abstract

14 patients with osteolytic bone disease due to breast cancer or myeloma, 7 of whom had hypercalcaemia, received oral treatment with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Serum-calcium dropped to low normal values in all 14 patients, accompanied by a decrease in urine calcium and hydroxyproline excretion-rate. The results show that A.P.D. may inhibit tumour-induced osteolysis.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

86043

Citation

van Breukelen, F J., et al. "Inhibition of Osteolytic Bone Lesions By (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)." Lancet (London, England), vol. 1, no. 8120, 1979, pp. 803-5.
van Breukelen FJ, Bijvoet OL, van Oosterom AT. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979;1(8120):803-5.
van Breukelen, F. J., Bijvoet, O. L., & van Oosterom, A. T. (1979). Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (London, England), 1(8120), 803-5.
van Breukelen FJ, Bijvoet OL, van Oosterom AT. Inhibition of Osteolytic Bone Lesions By (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):803-5. PubMed PMID: 86043.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). AU - van Breukelen,F J, AU - Bijvoet,O L, AU - van Oosterom,A T, PY - 1979/4/14/pubmed PY - 1979/4/14/medline PY - 1979/4/14/entrez SP - 803 EP - 5 JF - Lancet (London, England) JO - Lancet VL - 1 IS - 8120 N2 - 14 patients with osteolytic bone disease due to breast cancer or myeloma, 7 of whom had hypercalcaemia, received oral treatment with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Serum-calcium dropped to low normal values in all 14 patients, accompanied by a decrease in urine calcium and hydroxyproline excretion-rate. The results show that A.P.D. may inhibit tumour-induced osteolysis. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/86043/Inhibition_of_osteolytic_bone_lesions_by__3_amino_1_hydroxypropylidene__1_1_bisphosphonate__A_P_D___ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(79)91319-9 DB - PRIME DP - Unbound Medicine ER -